RecruitingPhase 3NCT06666855

A Phase III Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension in China

Studying Medullary sponge kidney

Last synced from ClinicalTrials.gov May 12, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Santen Pharmaceutical Co., Ltd.
Intervention: DE-117B Eye Drops(drug)
Enrollment: 338 target
Eligibility: 18 years · All sexes
Timeline: 2024 – 2026

Study locations (25)

Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China
Beijing Hospital, Beijing, China
Beijing Tongren Hospital, Capital Medical University, Beijing, China
Peking University Third Hospital, Beijing, China
Zhongshan Ophthalmic Center, Guangzhou, China
Affiliated Hospital of Guizhou Medical University, Guiyang, China
The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China
Zhejiang Provincial People's Hospital, Hangzhou, China
Jinan Second People's Hospital (Jinan eye hospital), Jinan, China
The Second Hospital & Clinical Medicial Lanzhou University, Lanzhou, China
Luoyang third people's hospital, Luoyang, China
Qingdao Eye Hospital of Shandong First Medical University, Qingdao, China
Shanghai Eye Disease Prevention And Treatment Center/Shanghai Eye Hospital, Shanghai, China
Joint Shantou International Eye Center of Shantou University and the Chinese University of Hong Kong, Shantou, China
Shanxi eye hospital, Shanxi, China
+10 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06666855 on ClinicalTrials.gov

Other trials for Medullary sponge kidney

Additional recruiting or active studies for the same condition.

See all trials for Medullary sponge kidney →

← Back to all trials